Physical Sciences-Oncology Centers

COTA, Inc. Announces Seven Upcoming Poster Presentations at the 2022 American Society of Hematology Annual Meeting

Retrieved on: 
Thursday, December 1, 2022

NEW YORK, Dec. 1, 2022 /PRNewswire/ -- COTA, Inc. ,an oncology real-world data and analytics company, announced that seven abstracts leveraging COTA's oncology real-world data (RWD) will be presented at the 64th American Society of Hematology (ASH) Annual Meeting taking place in New Orleans, Louisiana, from December 1013, 2022.

Key Points: 
  • NEW YORK, Dec. 1, 2022 /PRNewswire/ -- COTA, Inc. ,an oncology real-world data and analytics company, announced that seven abstracts leveraging COTA's oncology real-world data (RWD) will be presented at the 64th American Society of Hematology (ASH) Annual Meeting taking place in New Orleans, Louisiana, from December 1013, 2022.
  • "There is a continuous need to better understand how emerging therapies are impacting patients in everyday healthcare settings," said C.K.
  • COTA co-authored three of the seven abstracts accepted for poster presentation at the ASH conference.
  • The accepted poster presentations leveraging COTA's oncology real-world data include:

Pharmaceutical Industry Oncology Veteran Rohit Borker to join AESARA as VP, Oncology.

Retrieved on: 
Monday, October 17, 2022

AESARA is pleased to announce the appointment of Rohit Borker as VP, Oncology, at AESARA, a digital-forward market access agency that develops innovative and trusted solutions to power transformative market access.

Key Points: 
  • AESARA is pleased to announce the appointment of Rohit Borker as VP, Oncology, at AESARA, a digital-forward market access agency that develops innovative and trusted solutions to power transformative market access.
  • Rohit has completed multiple Value Based Pricing (VBP) initiatives and HTA models to influence drug pricing at C-Suite levels, Outcomes- and Value-based Contracts (OBC/VBC) with multiple organized payer systems.
  • AESARA is a market access agency with a focused purpose to impact healthcare decision-making to improve peoples lives.
  • Established in 2016, we are a woman and minority-owned company with biopharma seasoned industry professionals in the U.S., Canada, and Europe.

LUNGevity to Present Three Research Abstracts at 2022 World Lung Conference

Retrieved on: 
Tuesday, August 9, 2022

WASHINGTON, Aug. 9, 2022 /PRNewswire/ -- LUNGevity Foundation, the nation's leading lung cancer-focused nonprofit organization, is pleased to report that three of our Patient-Focused Research Center (Patient FoRCe) studies have been selected to be presented at the 2022 World Conference on Lung Cancer (WCLC) to be held August 6-9, 2022, in Vienna, Austria.  

Key Points: 
  • WASHINGTON, Aug. 9, 2022 /PRNewswire/ -- LUNGevity Foundation, the nation's leading lung cancer-focused nonprofit organization, is pleased to report that three of our Patient-Focused Research Center (Patient FoRCe) studies have been selected to be presented at the 2022 World Conference on Lung Cancer (WCLC) to be held August 6-9, 2022, in Vienna, Austria.
  • Lung cancer healthcare providers work hard to deliver quality care to patients but are one piece of the puzzle.
  • The three abstracts presented at WCLC 2022 reiterate the importance of integrating the patient and caregiver perspective in both clinical research and healthcare delivery.
  • LUNGevity Foundation is the nation's leading lung cancer organization focused on improving outcomes for people with lung cancer.

FDA Approves First Targeted Therapy for HER2-Low Breast Cancer

Retrieved on: 
Friday, August 5, 2022

This is the first approved therapy targeted to patients with the HER2-low breast cancer subtype, which is a newly defined subset of HER2-negative breast cancer.

Key Points: 
  • This is the first approved therapy targeted to patients with the HER2-low breast cancer subtype, which is a newly defined subset of HER2-negative breast cancer.
  • It is estimated that 287,850 new cases of female breast cancer will be diagnosed in 2022 in the U.S.
  • Of that proportion of breast cancer diagnoses, about 60% of patients previously classified as having HER2-negative subtype can now be considered as HER2-low.
  • The results showed improvement in both progression-free survival and overall survival in people with unresectable or metastatic HER2-low breast cancer.

Jazz Pharmaceuticals Presents Positive Data from Phase 2/3 Trial of Rylaze® (asparaginase erwinia chrysanthemi (recombinant)-rywn) in Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma at the ASCO 2022 Annual Meeting

Retrieved on: 
Tuesday, June 7, 2022

DUBLIN, June 7, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced positive results from a Phase 2/3 trial, developed and conducted in close collaboration with the Children's Oncology Group (COG), evaluating the intramuscular (IM) administration of Rylaze® (asparaginase erwinia chrysanthemi (recombinant)-rywn) in adult and pediatric patients with acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) who have developed hypersensitivity to an E. coli-derived asparaginase. These results will be presented as an oral presentation today at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting.

Key Points: 
  • Females of reproductive potential should use effective contraception (other than oral contraceptives) during treatment and for 3 months following the final dose.
  • Do not breastfeed while receiving RYLAZE and for 1 week after the final dose.
  • Tell your healthcare provider if there are any side effects that are bothersome or that do not go away.
  • We have a diverse portfolio of marketed medicines and novel product candidates, from early-to late-stage development, in neuroscience and oncology.

Jazz Pharmaceuticals Presents Positive Data from Phase 2/3 Trial of Rylaze® (asparaginase erwinia chrysanthemi (recombinant)-rywn) in Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma at the ASCO 2022 Annual Meeting

Retrieved on: 
Tuesday, June 7, 2022

DUBLIN, June 7, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced positive results from a Phase 2/3 trial, developed and conducted in close collaboration with the Children's Oncology Group (COG), evaluating the intramuscular (IM) administration of Rylaze® (asparaginase erwinia chrysanthemi (recombinant)-rywn) in adult and pediatric patients with acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) who have developed hypersensitivity to an E. coli-derived asparaginase. These results will be presented as an oral presentation today at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting.

Key Points: 
  • Females of reproductive potential should use effective contraception (other than oral contraceptives) during treatment and for 3 months following the final dose.
  • Tell your healthcare provider if there are any side effects that are bothersome or that do not go away.
  • We have a diverse portfolio of marketed medicines and novel product candidates, from early-to late-stage development, in neuroscience and oncology.
  • Asparaginase activity levels and monitoring in patients with acute lymphoblastic leukemia.Leukemia & Lymphoma.

Naveris Announces Abstract Accepted for Presentation at the 2022 American Society for Clinical Oncology (ASCO) Annual Meeting

Retrieved on: 
Friday, June 3, 2022

Naveris, Inc. announces the presentation of an abstract related to its flagship diagnostic test for TTMV-HPV DNA (NavDx) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting taking place from June 3 through June 7, 2022 in Chicago and virtually.

Key Points: 
  • Naveris, Inc. announces the presentation of an abstract related to its flagship diagnostic test for TTMV-HPV DNA (NavDx) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting taking place from June 3 through June 7, 2022 in Chicago and virtually.
  • Results of TTMV-HPV DNA testing in the NRG-HN002 phase II clinical trial for patients with p16-positive oropharynx cancer treated with intensity-modulated radiation therapy (IMRT), with or without cisplatin chemotherapy, will be shared in the presentation.
  • The company applies its innovative and patented technology to develop molecular diagnostics which enable earlier detection of viral cancers.
  • Naveris' first commercial-stage diagnostic, NavDx, is a blood test that supports the clinical management of patients with HPV-driven cancers.

Amber Specialty Pharmacy Added to Eisai’s LENVIMA® Network

Retrieved on: 
Wednesday, May 11, 2022

Amber Specialty Pharmacy, a Hy-Vee, Inc. subsidiary, is a pioneer and leader in the specialty pharmacy industry with more than 23 years of experience providing specialized care for persons with chronic, complex medical conditions.

Key Points: 
  • Amber Specialty Pharmacy, a Hy-Vee, Inc. subsidiary, is a pioneer and leader in the specialty pharmacy industry with more than 23 years of experience providing specialized care for persons with chronic, complex medical conditions.
  • Amber Specialty Pharmacy has built an exceptional reputation by providing personalized support and quality clinical care to patients and families.
  • Amber Specialty Pharmacy is accredited by the Utilization Review Accreditation Commission (URAC) and the Accreditation Commission for Health Care (ACHC).
  • Amber Specialty Pharmacy was named the 2020 Specialty Pharmacy of the Year by the National Association of Specialty Pharmacy.

Marengo Therapeutics Appoints Ke Liu, MD, PhD, and Bruce Chabner, MD, to Key Leadership Roles, Strengthening Marengo's Development Team and Supporting Translation to the Clinic

Retrieved on: 
Monday, May 9, 2022

CAMBRIDGE, Mass., May 9, 2022 /PRNewswire/ -- Marengo Therapeutics, Inc., a company pioneering novel therapeutics that directly target the Vβ chain of the T cell receptor (TCR) to activate the right T cell subsets to fight cancer, today announced the appointment of Ke Liu, M.D., Ph.D., as Chief Development Officer, as well as Bruce Chabner, M.D., as Senior Strategic Advisor. Dr. Liu will lead Marengo's clinical development and regulatory strategy, while Dr. Chabner will serve in an advisory capacity to the Marengo leadership team. As seasoned veterans of oncology drug development, Dr. Liu and Dr. Chabner will bring their significant expertise to Marengo as the company advances its STAR (Selective T Cell Activation Repertoire) platform to clinical trials in patients.

Key Points: 
  • Dr. Liu will lead Marengo's clinical development and regulatory strategy, while Dr. Chabner will serve in an advisory capacity to the Marengo leadership team.
  • "Ke's clinical and regulatory expertise in oncology and Bruce's instrumental contribution to cancer research have yielded unparalleled breakthroughs in the field.
  • The addition of such well-respected experts in the oncology space further supports progress of Marengo's novel T cell therapeutics into the clinic."
  • "I am thrilled to be joining Marengo at a key inflection point for the company's growth," said Dr. Liu.

Massive Bio and Amber Specialty Pharmacy Announce Nationwide Partnership to Revolutionize Digitally Enabled Oncology Clinical Trial Recruitment through AI Technology Platform

Retrieved on: 
Tuesday, May 3, 2022

Amber Specialty Pharmacy is dedicated to meeting the clinical, emotional, and financial needs of cancer patients and their caregivers.

Key Points: 
  • Amber Specialty Pharmacy is dedicated to meeting the clinical, emotional, and financial needs of cancer patients and their caregivers.
  • Massive Bios AI technology platform and expertise in cancer clinical trials are fully aligned with these goals, resulting in improved health outcomes and reduced costs for the industry, Williams added.
  • Amber Specialty Pharmacy has built an exceptional reputation by providing personalized support and quality clinical care to patients and families.
  • Amber Specialty Pharmacy was named the 2020 Specialty Pharmacy of the Year by the National Association of Specialty Pharmacy.